Clarifying the Role of the Mantel-Haenszel Risk Difference Estimator in Randomized Clinical Trials
厘清随机临床试验中 Mantel–Haenszel 风险差估计量的作用AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要核心为随机试验平均处理效应、分层协变量调整及其稳健推断。
厘清随机临床试验中 Mantel–Haenszel 风险差估计量的作用AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
The Mantel-Haenszel (MH) risk difference estimator, commonly used in randomized clinical trials for binary outcomes, calculates a weighted average of stratum-specific risk difference estimators. Traditionally, this method requires the stringent assumption that risk differences are homogeneous across strata, also known as the common (constant) risk difference assumption. In our article, we relax this assumption and adopt a modern perspective, viewing the MH risk difference estimator as an approach for covariate adjustment in randomized clinical trials, distinguishing its use from that in meta-analysis and observational studies. We demonstrate that, under reasonable restrictions on risk difference variability, the MH risk difference estimator consistently estimates the average treatment effect within a standard super-population framework, which is often the primary interest in randomized clinical trials, in addition to estimating a weighted average of stratum-specific risk differences. We rigorously study its properties under the large-stratum and sparse-stratum asymptotic regimes, as well as under mixed-regime settings. Furthermore, for either estimand, we propose a unified robust variance estimator that improves over the popular variance estimators by Greenland and Robins (1985) and Sato et al. (1989) and has provable consistency across these asymptotic regimes, regardless of assuming common risk differences. Extensions of our theoretical results also provide new insights into the Mantel-Haenszel test, the post-stratification estimator, and settings with multiple treatments. Our findings are thoroughly validated through simulations and a clinical trial example.
Two frequent approaches for identifying structural VARs are external instruments, which carry economic content but are often weak, and non-Gaussianity of the shocks, which provides statistical identification but carries no economic meaning. We combine the two strategies in a single generalized method of moments framework. This hybrid approach point-identifies the target shocks while also identifying the non-target shocks up to sign and ordering. Under suitable rank…
The conditional average treatment effect (CATE) is frequently estimated in clinical studies to refute a homogeneous treatment effect hypothesis. Under this regime, all patients making up the population experience identical benefit from a given treatment relative to a comparator. Uncovering heterogeneous treatment effects through inference about the CATE, however, requires that covariates truly modifying the treatment effect be reliably collected at baseline. CATE-based…
内生性检验:一种基于矩的贝叶斯方法
A standard assumption in the Bayesian estimation of linear regression models is that the regressors are exogenous in the sense that they are uncorrelated with the model error term. In practice, however, this assumption can be invalid. In this article, using the exponentially tilted empirical likelihood (ETEL) framework, we develop a Bayes factor test for endogeneity that compares a base model that is correctly specified under exogeneity but misspecified under endogeneity…
We study difference-in-differences designs in which all units are initially untreated and later receive heterogeneous, strictly positive treatment doses. When quasi-untreated units receive doses close to zero, a difference-in-difference estimand using those units as the control group identifies a weighted average treatment effect per unit of treatment, under a parallel-trends assumption. We develop a nonparametric estimator and bias-corrected confidence intervals for this…
伪面板事件研究:可信应用的计量经济学基础
Event studies with panel data are widely used to estimate treatment effects. With repeated cross-sections, future treatment dates are unobserved for untreated individuals. Pseudo-panel event studies impute pre-treatment outcomes of the treated using matched untreated individuals. This paper establishes identification in such designs and characterizes bias when identification conditions fail. I show that the pseudo-panel regression is equivalent to weighted least squares with…
自适应实验中策略改进价值的推断
In this paper, we develop an asymptotically normal estimator for the value of policy improvement (VPI) under adaptively collected data. This value, which is defined as the gap between the value of the best treatment policy in a class and that of a baseline policy, gauges whether or not it is worth deploying a personalized treatment policy. Building an estimator for the VPI is naturally more difficult than estimating the value of a fixed policy. This is because, in addition…